Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay PALO ALTO, Calif., January 08, 2026--(BUSINESS WIRE)--Guardant ...
Earlier this week, Guardant Health announced that its FDA-approved Shield blood test for colorectal cancer screening is now covered with no copay for average-risk active-duty U.S. service members and ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...
FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...
It’s estimated that 129 million people in the US are living with at least one major chronic disease. That’s nearly one in three Americans. And every year, around 2 million Americans are diagnosed with ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with ...
President Donald Trump's "Golden Dome," a cutting-edge missile defense system meant to intercept threats targeting the American homeland, will make its debut in Guam, Del. James Moylan told Fox News ...
Under the multi-year agreement, the companies will use Guardant's portfolio of liquid and tissue biopsy tests to help enroll patients in Merck's global clinical studies.
The US Court of Appeals for the Federal Circuit remanded the case to the Patent Trial and Appeal Board to consider patent validity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results